Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: The MACH-1 study

Circulation

Volumn 101, Issue 7, 2000, Pages 758-764

  Levine, T Barry ^a   Bernink, Peter J L M ^b   Caspi, Abraham ^b   Elkayam, Uri ^b   Geltman, Edward M ^b   Greenberg, Barry ^b   McKenna, William J ^b   Ghali, Jalal K ^b   Giles, Thomas D ^b   Marmor, Alon ^b   Reisin, Leonardo H ^b   Ammon, Susan ^b   Lindberg, Elisabet ^b  

^a Botsford Hospital   (United States)

^b NONE

Author keywords

Calcium channels; Heart failure; Mibefradil

Indexed keywords

CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; MIBEFRADIL; PLACEBO;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HEART FAILURE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERTIGO;

EID: 0034700973     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.7.758     Document Type: Article

References (24)

1. Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola S. A prospective, randomized, double-blind, crossover study to compare the efficacy of and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation. 1990;82:1954-1961.
2. Multicenter Diltiazem Postinfarction Trial Research Group, The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319:385-392.
3. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248-254.
4. Cohn J. The management of chronic heart failure. N Engl J Med. 1996; 335:490-498.
5. Katz A. Calcium channel diversity in the cardiovascular system. J Am Coll Cardiol. 1996;28:522-529.
6. 2+ channels. Trends Pharmacol Sci. 1991;12:349-354.
7. Hermsmeyer K, Erne P. Vascular muscle ion channels and cellular calcium regulation in hypertension. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. 2nd ed. New York, NY: Raven Press; 1995:673-683.
8. Bean B. Pharmacology of calcium channels in cardiac muscle, vascular muscle, and neurons. Am J Hypertens. 1991;4:406S-411S.
9. 2+ current is expressed in hypertrophied adult feline left ventricular myocytes. Circ Res. 1993;73:777-782.
10. Furukawa T, Ito H, Nitta J, Tsujino M, Adachi S, Hiroe M, Marumo F, Sawanobori T, Hiraoka M. Endothelin-1 enhances calcium entry through T-type calcium channels in cultured neonatal rat ventricular myocytes. Circ Res. 1992;71:1242-1253.
11. Clozel J-P, Banken L, Osterrieder W. Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: comparison with verapamil. J Cardiovasc Pharmacol. 1989;14:713-721.
12. Véniant M, Clozel J-P, Hess P, Wolfgang R. Hemodynamic profile of Ro 40-5967 in conscious rats: comparison with diltiazem, verapamil, and amlodipine. J Cardiovasc Pharmacol. 1991;18(suppl 10):S55-S58.
13. Schmitt R, Kleinbloesem C, Belz G, Schroeter V, Feifel U, Pozenel H, Kirch W, Halabi A, Woittiez A-J, Welker H, van Brummelen P. Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension. Clin Pharmacol Ther. 1992;52:314-323.
14. Mulder P, Richard V, Compagnon P, Henry J-P, Lallemand F, Clozel J-P, Koen R, Macé B, Thuillez C. Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure. J Am Coll Cardiol. 1997;29:416-421.
15. Rousseau M, Hayashida W, van Eyll C, Hess O, Benedict C, Ahn S, Chapelle F, Kobrin I, Pouleur H. Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocker, mibefradil, in patients with varying degrees of left ventricular systolic dysfunction. J Am Coll Cardiol. 1996;28:972-979.
16. Höglund C, Cifkova R, Mimran A, Tenczer J, Watt A, Wilkins M, Lindberg E. A comparison of the effects of mibefradil and atenolol on regression of left ventricular hypertrophy in hypertensive patients. Cardiology. 1998;89:263-270.
17. Oparil S, Kobrin I, Abernethy D, Levine B, Reif M, Shepherd A. Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension. Am J Hypertens. 1997;10:735-742.
18. Bakx A, van der Wall E, Braun S, Emanuelsson H, Bruschke A, Kobrin I. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Am Heart J. 1995;130:748-757.
19. Tzivoni D, Kadr H, Braat S, Rutsch W, Ramires J, Kobrin I. Efficacy of mibefradil in comparison to amlodipine in suppressing exercise-induced and daily silent ischemia: results of a multicenter, placebo-controlled trial. Circulation. 1997;96:2557-2564.
20. Franciosa J, Park M, Levine T. Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure. Am J Cardiol. 1981;47:33-39.
21. Katecholamin-Analysator II: Serum, plasma. In: Methode Handbook. Darmstudt. Germany: MERCK Diagnostica; 1990.
22. O'Brien P, Fleming T. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549-556.
23. Brogden R, Markham A. Mibefradil: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of hypertension and angina pectoris. Drugs. 1997;54:774-793.
24. Fabre G, Julian B, Saint-Aubert B, Joyeux H, Berger Y. Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab Dispos. 1993;21:978-985.